Clinical Research of Human Mesenchymal Stem Cells in the Treatment of COVID-19 Pneumonia

Clinical Research of Human Mesenchymal Stem Cells in the Treatment of COVID-19 Pneumonia

Sponsors

Lead sponsor: Puren Hospital Affiliated to Wuhan University of Science and Technology

Collaborator: Shanghai University
Qingdao Co-orient Watson Biotechnology group co. LTD
Basic Medical Sciences, Chinese Academy of Medical Sciences

Source Puren Hospital Affiliated to Wuhan University of Science and Technology
Brief Summary

The COVID-19 pneumonia has grown to be a global public health emergency since patients were first detected in Wuhan, China, in December 2019, which spread quickly to worldwide and presented a serious threat to public health. It is mainly characterized by fever, dry cough, shortness of breath and breathing difficulties. Some patients may develop into rapid and deadly respiratory system injury with overwhelming inflammation in the lung. Currently, no specific drugs or vaccines are available to cure the patients with COVID-19 pneumonia. Hence, there is a large unmet need for a safe and effective treatment for COVID-19 pneumonia patients, especially the critically ill cases. The significant clinical outcome and well tolerance was observed by the adoptive transfer of allogenic MSCs. We proposed that the adoptive transfer therapy of MSCs might be an ideal choice to be used. We expect to provide new options for the treatment of critically ill COVID-19 pneumonia patients and contribute to improving the quality of life of critically ill patients.

Detailed Description

Since December 2019, novel coronavirus disease 2019 (COVID-19) in Wuhan has been fierce and spread rapidly. As of 24:00 on March 4, 2020, China has reported a total of 80567 confirmed cases, 5952 existing critically ill cases, and 3016 dead cases. The COVID-19 pneumonia has grown to be a global public health emergency since patients were first detected in Wuhan, China, in December 2019, which spread quickly to 26 countries worldwide and presented a serious threat to public health. It is mainly characterized by fever, dry cough, shortness of breath and breathing difficulties. Some patients may develop into rapid and deadly respiratory system injury with overwhelming inflammation in the lung. Currently, no specific drugs or vaccines are available to cure the patients with COVID-19 infection. Hence, there is a large unmet need for a safe and effective treatment for COVID-19 infected patients, especially the critically ill cases.

Recently, some clinical researches about the COVID-19 published in The Lancet and The New England Journal of Medicine suggested that massive inflammatory cell infiltration and inflammatory cytokines secretion were found in patients' lungs, alveolar epithelial cells and capillary endothelial cells were damaged, causing acute lung injury. Several reports demonstrated that the first step of the HCoV-19 pathogenesis is that the virus specifically recognizes the angiotensin I converting enzyme 2 receptor (ACE2) by its spike Protein. This receptor is abundant in lung and small intestinal tissues, but is also highly expressed in vascular endothelial cells and smooth muscle cells in almost all organs, including the nervous system and skeletal muscle. The main organ injured by the HCoV-19 is the lung. In fact, HCoV-19 can also involve the nervous system, digestive system, urinary system, blood system and other systems. Therefore, when the initial symptom is discomfort of other systems in the early stage, it is often easy to be misdiagnosed and delay treatment. Moreover, the HCoV-19 is a noncellular form consisting of RNA and protein, which cannot be copied independently. It needs to bind to cell surface receptors to enter the cell to complete the replication, and then be released again. Therefore, once the HCoV-19 enters the blood circulation, it can easily spread to all systems throughout the body, which may be the pathological mechanism that the HCoV-19 directly or indirectly causes neurological symptoms.

It seems that the key to cure the COVID-19 pneumonia is to inhibit the inflammatory response, resulting to reduce the damage of alveolar epithelial cells and endothelial cells and repair the function of the lung. MSCs, owing to their powerful immunomodulatory ability, may have beneficial effects on preventing or attenuating the cytokine storm.

Mesenchymal stem cells (MSCs) are widely used in basic research and clinical application. They are proved to migrate to damaged tissues, exert antiinflammatory and immunoregulatory functions, promote the regeneration of damaged tissues and inhibit tissue fibrosis. MSCs play a positive role mainly in two ways, namely immunomodulatory effects and differentiation abilities. MSCs can secrete many types of cytokines by paracrine secretion or make direct interactions with immune cells, leading to immunomodulation. Studies have shown that MSCs can significantly reduce acute lung injury in mice caused by H9N2 and H5N1 viruses by reducing the levels of proinflammatory cytokines and the recruitment of inflammatory cells into the lungs. Compared with MSCs from other sources, human umbilical cord-derived MSCs (UC-MSCs) have been widely applied to various diseases due to their convenient collection, no ethical controversy, low immunogenicity, and rapid proliferation rate.

Here we conducted an MSC transplantation pilot study to explore their therapeutic potential for COVID-19 pneumonia patients. To explore the effective treatment of COVID-19 pneumonia for the current prevention and control of novel coronavirus pneumonia to find a key and effective clinical treatment means, to fight against the epidemic.

Overall Status Recruiting
Start Date February 1, 2020
Completion Date June 30, 2020
Primary Completion Date June 30, 2020
Phase Phase 1/Phase 2
Study Type Interventional
Primary Outcome
Measure Time Frame
The immune function (TNF-α 、IL-1β、IL-6、TGF-β、IL-8、PCT、CRP) Observe the immune function of the participants within 4 weeks
Blood oxygen saturation Monitor blood oxygen saturation of the participants within 4 weeks
Secondary Outcome
Measure Time Frame
Rate of mortality within 28-days At baseline, Day 1, Day 2, Day 7, Week 2, Week 3, Week 4
Size of lesion area by chest imaging At baseline, Day 1, Day 2, Day 7, Week 2, Week 3, Week 4
CD4+ and CD8+ T cells count At baseline, Day 1, Day 2, Day 7, Week 2, Week 3, Week 4
Peripheral blood count recovery time At baseline, Day 1, Day 2, Day 7, Week 2, Week 3, Week 4
Duration of respiratory symptoms (fever, dry cough, difficulty breathing, etc.) At baseline, Day 1, Day 2, Day 7, Week 2, Week 3, Week 4
COVID-19 nucleic acid negative time At baseline, Day 1, Day 2, Day 7, Week 2, Week 3, Week 4
Enrollment 30
Condition
Intervention

Intervention type: Biological

Intervention name: UC-MSCs

Description: 1*10E6 UC-MSCs /kg body weight suspended in 100mL saline

Arm group label: UC-MSCs treatment group

Intervention type: Other

Intervention name: Placebo

Description: 100mL saline intravenously

Arm group label: Control group

Eligibility

Criteria:

Inclusion Criteria:

1. Male or female, 18 years old ≤ age ≤ 75years old;

2. CT image is characteristic of 2019 novel coronavirus pneumonia;

3. Laboratory confirmation of 2019-nCoV infection by reverse transcription polymerase chain reaction (RT-PCR);

4. In compliance with the 2019-nCoV pneumonia diagnosis standard (according to the novel coronavirus infection pneumonia diagnosis and treatment program (Trial Implementation Version 6) issued by the National Health and Medical Commission, and WHO 2019 new coronavirus guidelines standards): (A) increased breathing rate (≥30 beats / min), difficulty breathing, cyanosis of the lips; (B) in resting state, means oxygen saturation ≤93%; (C) partial pressure of arterial oxygen (PaO2) / Fraction of inspired oxygen (FiO2) ≤300 mmHg (1mmHg = 0.133kPa);

5. Participant or the authorized agent signed the informed consent form.

6. Agree to collect clinical samples.

Exclusion Criteria:

1. Malignant disease in the past five years;

2. Participant with no hope of survival were clinically predicted and only received hospice care, or those who were in a deep coma and did not respond to supportive treatment measures within three hours of admission.

3. Participant who are participating in other clinical trials or who have participated in other clinical trials within 3 months.

4. Cases of severe shock and respiratory failure.

Gender: All

Minimum age: 18 Years

Maximum age: 75 Years

Healthy volunteers: No

Overall Contact

Last name: Yan Liu, MD

Phone: +8613387517458

Email: [email protected]

Location
facility status contact Puren Hospital Affiliated to Wuhan University of Science and Technology Yan Liu, MD +8613387517458 [email protected]
Location Countries

China

Verification Date

April 2020

Responsible Party

Responsible party type: Sponsor

Keywords
Has Expanded Access No
Condition Browse
Number Of Arms 2
Arm Group

Arm group label: UC-MSCs treatment group

Arm group type: Experimental

Description: Participants will receive conventional and treatment with MSCs, MSCs were suspended in 100 mL of normal saline, and the total number of transplanted cells was calculated by 1*10E6 cells per kilogram of weight. This product is generally a course of treatment, a total of 1 time, depending on the condition of the need to be given again at an interval of 1 week.

Arm group label: Control group

Arm group type: Placebo Comparator

Description: Participants will receive conventional treatment and Placebo intravenously.

Study Design Info

Allocation: Randomized

Intervention model: Parallel Assignment

Primary purpose: Treatment

Masking: Triple (Participant, Care Provider, Outcomes Assessor)

Source: ClinicalTrials.gov